The stock of Pacira BioSciences Inc (PCRX) has gone up by 11.37% for the week, with a 5.24% rise in the past month and a 5.35% rise in the past quarter. The volatility ratio for the week is 3.43%, and the volatility levels for the past 30 days are 3.35% for PCRX. The simple moving average for the last 20 days is 12.84% for PCRX stock, with a simple moving average of -3.07% for the last 200 days.
Is It Worth Investing in Pacira BioSciences Inc (NASDAQ: PCRX) Right Now?
The price-to-earnings ratio for Pacira BioSciences Inc (NASDAQ: PCRX) is above average at 21.58x. The 36-month beta value for PCRX is also noteworthy at 0.85. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 3 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for PCRX is 45.19M, and at present, short sellers hold a 7.63% of that float. The average trading volume of PCRX on May 08, 2024 was 478.40K shares.
PCRX) stock’s latest price update
Pacira BioSciences Inc (NASDAQ: PCRX)’s stock price has increased by 13.22 compared to its previous closing price of 26.51. However, the company has seen a 11.37% increase in its stock price over the last five trading sessions. Seeking Alpha reported 2024-05-07 that Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Susan Mesco – Head of Investor Relations Frank Lee – Chief Executive Officer Charles Reinhart – Chief Financial Officer Jonathan Slonin – Chief Medical Officer Christian Pedetti – Senior Manager, Investor Relations Conference Call Participants Gregory Renza – RBC Capital Markets David Amsellem – Piper Sandler Gary Nachman – Raymond James Balaji Prasad – Barclays Operator Thank you for standing by. My name is Hermione and I will be your conference operator today.
Analysts’ Opinion of PCRX
Many brokerage firms have already submitted their reports for PCRX stocks, with JP Morgan repeating the rating for PCRX by listing it as a “Overweight.” The predicted price for PCRX in the upcoming period, according to JP Morgan is $45 based on the research report published on March 07, 2024 of the current year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see PCRX reach a price target of $42. The rating they have provided for PCRX stocks is “Outperform” according to the report published on December 20th, 2023.
TD Cowen gave a rating of “Outperform” to PCRX, setting the target price at $50 in the report published on August 03rd of the previous year.
PCRX Trading at 6.09% from the 50-Day Moving Average
After a stumble in the market that brought PCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.49% of loss for the given period.
Volatility was left at 3.35%, however, over the last 30 days, the volatility rate increased by 3.43%, as shares surge +7.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.37% upper at present.
During the last 5 trading sessions, PCRX rose by +11.17%, which changed the moving average for the period of 200-days by -18.70% in comparison to the 20-day moving average, which settled at $26.70. In addition, Pacira BioSciences Inc saw -11.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCRX starting from PACE GARY W, who sale 90,000 shares at the price of $30.60 back on Mar 08 ’24. After this action, PACE GARY W now owns 22,127 shares of Pacira BioSciences Inc, valued at $2,754,000 using the latest closing price.
PACE GARY W, the Director of Pacira BioSciences Inc, sale 28,257 shares at $30.81 during a trade that took place back on Mar 07 ’24, which means that PACE GARY W is holding 112,127 shares at $870,598 based on the most recent closing price.
Stock Fundamentals for PCRX
Current profitability levels for the company are sitting at:
- 0.15 for the present operating margin
- 0.78 for the gross margin
The net margin for Pacira BioSciences Inc stands at 0.12. The total capital return value is set at 0.07. Equity return is now at value 8.49, with 4.54 for asset returns.
Based on Pacira BioSciences Inc (PCRX), the company’s capital structure generated 0.32 points at debt to capital in total, while cash flow to debt ratio is standing at 0.44. The debt to equity ratio resting at 0.47. The interest coverage ratio of the stock is 12.92.
Currently, EBITDA for the company is 162.9 million with net debt to EBITDA at 1.63. When we switch over and look at the enterprise to sales, we see a ratio of 2.4. The receivables turnover for the company is 6.71for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.81.
Conclusion
In summary, Pacira BioSciences Inc (PCRX) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
